Chiron Corp.
Cubicin granted marketing approval in Europe
Published in Pharma Law Weekly, February 14th, 2006
The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein and Norway. Under the approval, Cubicin is indicated for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria. Cubicin is expected to become available in the United Kingdom and the Netherlands within the next few weeks, followed by additional European countries, in accordance with local legal regulations.
Gram-positive bacteria are a major cause of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-02-14)
More Articles from Pharma Law Weekly
- DUSA Pharmaceuticals, Inc.
Physicians sued for infringement of Levulan photodynamic therapy patents - Global Pharmatech, Inc.
Natural Pharmatech successfully transfers new drug patent - Lantibio, Inc.
Companies sign agreements for U.S. development and marketing of dry eye syndrome therapy - Laserscope
U.S. patent issued for photoselective vaporization methods of prostate and other tissues - Lorus Therapeutics Inc.
Cancer-focused biopharma company announces $21.6 million tax assisted financing - Medicare
Less than 18% of low-income seniors approved for new Medicare drug subsidies - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
